something there

http://www.livemint.com/Companies/3EWmQH2dwGuXg4UkIitcOJ/Cipla-inks-investment-pact-with-FIL-Capital-Investments.html

market cap 517 bn inr pe 32

New Delhi: Cipla on Saturday said it has inked an investment agreement with FIL Capital Investments (Mauritius) II Ltd for its consumer healthcare business. “Cipla Health Ltd and FIL Capital Investments (Mauritius) II Ltd have on 27 November 2015 signed an investment agreement,” Cipla said in a regulatory filing.

The investment is subject to approvals from the Foreign Investment Promotion Board (FIPB) and the Competition Commission of India (CCI), and the transfer of Cipla’s consumer healthcare business to Cipla Health Ltd, it added. The company, however, did not disclose the financial details of the agreement.

In July, Cipla’s board had approved an investment by Fidelity Growth Partners India and US-based Fidelity Biosciences, through FIL Capital Investments (Mauritius) II or its affiliates in its recently launched consumer healthcare business. Through the consumer healthcare business, Cipla has entered the over-the-counter (OTC) healthcare market in India.

Earlier, the Mumbai-based company’s board had approved divestment of its consumer healthcare business to Cipla Health, a wholly-owned subsidiary, by way of a slump sale for a consideration of Rs.10.5 crore. The Indian consumer healthcare is a $4 billion market and is growing at a CAGR of 15%. 

http://www.livemint.com/Industry/Lc94HIIqwdA0FNkJss4U7N/Cipla-weighs-legal-options-after-Delhi-high-courts-patent-r.html

Cipla is exploring all legal options in the wake of Delhi high court’s ruling that it has infringed Swiss drug major Hoffman-La Roche’s patent on lung cancer drug erlotinib hydrochloride sold under Tarceva.

“The division bench of the high court of Delhi has ruled that Cipla has infringed Roche’s patent on erlotinib, a drug used for lung cancer. However, the court has allowed Cipla to continue to sell the product,” Cipla said in a statement.

The court will also determine the quantum of damages Cipla owes to Roche after the former furnishes accounts, it added. “Cipla will explore all legal options available to it,” the company said.

A bench of justices Pradeep Nandrajog and Mukta Gupta on Friday noted that Cipla’s lung cancer medicine, erlocip, is one polymorphic form of the erlotinib hydrochloride compound, which may exist in several forms, and Roche’s patent claim is not limited to any one such version. The court, however, did not grant any injunction in favour of Roche by restraining Cipla, saying the patent in favour of the Swiss company will expire in March 2016.

The court, in its 106-page judgement, also said that as Cipla “could not establish prima facie that suit patent was obvious, its plea for invalidating Roche’s patent on the ground of obviousness fails”.

In a statement, Roche has said it “welcomes the decision of the division bench of the Delhi high court, which has upheld the patent covering erlotinib hydrochloride (Tarceva) and has found Cipla to have infringed the patent